S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Summary

RATIONALE: Monoclonal antibodies, such as CNTO 328, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well CNTO 328 works in treating patients with unresectable or metastatic kidney cancer.

Timeline

Start

—

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped: “withdrawal of support for drug supply”

Drugs

Indications